Why population resolution matters
Bulk viability obscures which cells respond. Multiparameter flow resolves drug effects within the malignant compartment and across immune populations, so efficacy and target biology are measured where they count.
A flow cytometry and immunophenotyping add-on quantifies antigen density and measures drug response within defined malignant populations — not in the bulk well.
Bulk viability obscures which cells respond. Multiparameter flow resolves drug effects within the malignant compartment and across immune populations, so efficacy and target biology are measured where they count.
Target marker expression on malignant vs. non-malignant cells — directly relevant to ADC, DACs, bispecific, and degrader programs.
Drug sensitivity within defined immunophenotypes (e.g., CD34+ leukemic stem cells, lymphoma subsets, plasma-cell compartments)
Study-specific panels with gating strategies and population viability profiles.
Layers onto any live-cell service to add population-level resolution, commonly paired with Combination Optimization and Immunotherapy Translational.
Key Deliverables
A scientist — not a sales desk — will scope a tailored study and return a design and timeline.
